Clinical Utility of Bone Markers in the Evaluation and Follow-up in Patients with Neoplastic Bone Diseases
Authors:
J. Štěpán; T. Zima 1; L. Petruželka 2
Authors place of work:
Revmatologický ústav, Praha
; Ústav klinické chemie a laboratorní diagnostiky 1. LF UK a VFN, Praha
1; Onkologická klinika 1. LF UK a VFN, Praha
2
Published in the journal:
Čas. Lék. čes. 2008; 147: 7-13
Category:
Review Article
Summary
The biochemical markers of bone remodeling reflect the rates of bone resorption and bone formation in the whole body rather than in segments of the skeleton. The markers cannot be used for a diagnosis of bone disease. However, they are a valuable tool in the differential diagnosis, in the assessment of fracture risk independent of bone mineral density and, in the monitoring treatments of metabolic and neoplastic bone diseases as well as the side effects of some drugs on bone (e.g., adjuvant treatment with selective inhibitors of aromatase). This review provides characteristics of the markers currently used to assess neoplastic bone diseases and, their clinical values for stratification and monitoring treatments. Currently used markers provide sufficient specificity. However, their sensitivities under various clinical situations have to be respected. The clinical utility of the markers requires their standardization and availability.
Key words:
bone, metastasis, multiple myeloma, osteoporosis, markers, monitoring.
Zdroje
1. Hamaoka, T., Madewell, J. E., Podoloff, D. A. et al.: Bone imaging in metastatic breast cancer. J. Clin. Oncol., 2004, 22, s. 2942–2953.
2. Štěpán, J.: Laboratorní diagnostika kostního metabolismu. In: Zima, T. (ed.) Laboratorní diagnostika. 2. ed. Praha, Galén, 2007, s. 229–269.
3. Delmas, P. D., Eastell, R., Garnero, P. et al.: The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int., 2000, 11 (Suppl. 6), s. S2–S17.
4. Wymenga, L. F., Groenier, K., Schuurman, J. et al.: Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis. BJU Int., 2001, 88, s. 231–235.
5. Lipton, A., Ali, S. M., Leitzel, K. et al.: Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 2002, 8, s. 2306–2310.
6. Depil, S., Mathiot, C., Leleu, X. et al.: Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma. Br. J. Haematol., 2005, 129, s. 706–707.
7. Bellahcene, A., Menard, S., Bufalino, R. et al.: Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int. J. Cancer, 1996, 69, s. 350–353.
8. De Pinieux, G., Flam, T., Zerbib, M. et al.: Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinicopathological and immunohistochemical study of 43 cases. J. Urol., 2001, 166, s. 1924–1930.
9. Michalská, D., Štěpán, J. J., Basson, B. R., Pavo, I.: The effect of raloxifene after discontinuation of long–term alendronate treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab., 2006, 91, s. 870–877.
10. Jukkola, A., Tahtela, R., Tholix, E. et al.: Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP. Cancer Res., 1997, 57, s. 5517–5520.
11. Behrens, P., Bruns, J., Ullrich, K. P. et al.: Pyridinoline cross–links as markers for primary and secondary bone tumors. Scand. J. Clin. Lab. Inves., 2003, 63, s. 37–44.
12. Pecherstorfer, M., Zimmer-Roth, I., Schilling, T. et al.: The diagnostic value of urinary pyridinium cross–links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J. Clin. Endocrinol. Metab., 1995, 80, s. 97–103.
13. Jakob, C., Zavrski, I., Heider, U. et al.: Bone resorption parameters [carboxy–terminal telopeptide of type–I collagen (ICTP), amino–terminal collagen type–I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur. J. Haematol., 2002, 69, s. 37–42.
14. Oremek, G. M., Weis, A., Sapoutzis, N., Sauer-Eppel, H.: Diagnostic value of bone and tumour markers in patients with malignant diseases. Anticancer Res., 2003, 23, s. 987–990.
15. Abildgaard, N., Brixen, K., Kristensen, J. E. et al.: Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre–treatment levels of S-ICTP and U‑Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br. J. Haematol., 2003, 120, s. 235–242.
16. Ulrich, U., Rhiem, K., Schmolling, J. et al.: Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer. Arch. Gynecol. Obstet., 2001, 264, s. 186–190.
17. Bačovský, J., Ščudla, V., Vytřasová, M. et al.: Monitoring of bone resorption and bone formation in multiple myeloma. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub, 2002, 146, s. 59–61.
18. Jakob, C., Zavrski, I., Heider, U. et al.: Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin. Cancer Res., 2003, 9, s. 3047–3051.
19. Abildgaard, N., Brixen, K., Eriksen, E. F. et al.: Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica, 2004, 89, s. 567–577.
20. Chao, T. Y., Ho, C. L., Lee, S. H. et al.: Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients. Journal of biomedical science, 2004, 11, s. 511–516.
21. Fedarko, N. S., Jain, A., Karadag, A. et al.: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin. Cancer Res., 2001, 7, s. 4060–4066.
22. Fonseca, R., Trendle, M. C., Leong, T. et al.: Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br. J. Haematol., 2000, 109, s. 24–29.
23. Woitge, H. W., Pecherstorfer, M., Horn, E. et al.: Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br. J. Cancer, 2001, 84, s. 344–351.
24. Terpos, E., Szydlo, R., Apperley, J. F. et al.: Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood, 2003, 102, s. 1064–1069.
25. Štěpán, J. J., Neuwirtová, R., Pacovský, V. et al.: Biochemical assessment of bone disease in multiple myeloma. Clin. Chim. Acta, 1984, 142, s. 203–209.
26. Tian, E., Zhan, F., Walker, R. et al.: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Eng.l J. Med., 2003, 349, s. 2483–2494.
27. Yaccoby, S., Pearse, R. N., Johnson, C. L. et al.: Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br. J. Haematol., 2002, 116, s. 278–290.
28. Coleman, R. E., Major, P., Lipton, A. et al.: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol., 2005, 23, s. 4925–4935.
29. Ali, S. M., Demers, L. M., Leitzel, K. et al.: Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone–only metastasis. Ann. Oncol., 2004, 15, s. 455–459.
30. Brown, J. E., Thomson, C. S., Ellis, S. P. et al.: Bone resorption predicts for skeletal complications in metastatic bone disease. Br. J. Cancer, 2003, 89, s. 2031–2037.
31. Berenson, J. R., Vescio, R., Henick, K. et al.: A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer, 2001, 91, s. 144–154.
32. Terpos, E., de la Fuente, J., Szydlo, R. et al.: Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int. J. Cancer., 2003, 106(3), s. 455–457.
33. Lipton, A., Demers, L., Curley, E. et al.: Markers of bone resorption in patients treated with pamidronate. Eur. J. Cancer, 1998, 34, s. 2021–2026.
34. Berenson, J. R., Rosen, L. S., Howell, A. et al.: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer, 2001, 91, s. 1191–1200.
35. Vinholes, J. J., Purohit, O. P., Abbey, M. E. et al.: Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann. Oncol., 1997, 8, s. 1243–1250.
36. Jagdev, S. P., Purohit, P., Heatley, S. et al.: Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann. Oncol., 2001, 12, s. 1433–1438.
37. Body, J. J., Diel, I. J., Lichinitzer, M. et al.: Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br. J. Cancer, 2004, 90, s. 1133–1137.
38. Richer, E., Lewis, M. A., Odvina, C. V. et al.: Reduction in normalized bone elasticity following long–term bisphosphonate treatment as measured by ultrasound critical angle reflectometry. Osteoporos Int., 2005, 16, s. 1384–1392.
39. Štěpán, J. J., Burr, D. B., Pavo, I. et al.: Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone, 2007, 41, s. 378–385.
40. Ott, S. M.: Fractures after long–term alendronate therapy. J. Clin. Endocrinol. Metab., 2001, 86, s. 1835–1836.
41. Dunstan, C. R., Felsenberg, D., Seibel, M. J.: Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nature clinical practice, 2007, 4, s. 42–55.
42. Clemons, M., Enright, K., Cesta, A. et al.: Do physicians follow systemic treatment and funding policy guidelines? The Canadian journal of clinical pharmacology, 2004, 11, 168–178.
43. Eastell, R., Hannon, R.: Long-term effects of aromatase inhibitors on bone. J. Steroid. Biochem. Mol. Biol., 2005, 95, s. 151–154.
44. Pandya, N., Morris, G. J.: Toxicity of aromatase inhibitors. Semin. Oncol., 2006, 33, s. 688–695.
45. Gnant, M. F., Mlineritsch, B, Luschin-Ebengreuth, G. et al.: Zoledronic acid prevents cancer treatment–induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone–responsive breast cancer. J. Clin. Oncol., 2007, 25, s. 820–828.
Štítky
Addictology Allergology and clinical immunology Anaesthesiology, Resuscitation and Inten Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric dermatology & STDs Paediatric gastroenterology Paediatric gynaecology Paediatric surgery Paediatric cardiology Paediatric nephrology Paediatric neurology Paediatric clinical oncology Paediatric ENT Paediatric pneumology Paediatric psychiatry Paediatric radiology Paediatric rheumatology Paediatric urologist Diabetology Endocrinology Pharmacy Clinical pharmacology Physiotherapist, university degree Gastroenterology and hepatology Medical genetics Geriatrics Gynaecology and obstetrics Haematology Hygiene and epidemiology Hyperbaric medicine Vascular surgery Chest surgery Plastic surgery Surgery Medical virology Intensive Care Medicine Cardiac surgery Cardiology Clinical speech therapy Clinical microbiology Nephrology Neonatology Neurosurgery Neurology Nuclear medicine Nutritive therapist Obesitology Ophthalmology Clinical oncology Orthodontics Orthopaedics ENT (Otorhinolaryngology) Anatomical pathology Paediatrics Pneumology and ftiseology Burns medicine Medical assessment General practitioner for children and adolescents Orthopaedic prosthetics Clinical psychology Radiodiagnostics Radiotherapy Rehabilitation Reproduction medicine Rheumatology Nurse Sexuology Forensic medical examiner Dental medicine Sports medicine Toxicology Traumatology Trauma surgery Urology Laboratory Home nurse Phoniatrics Pain management Health Care Dental Hygienist Medical studentČlánok vyšiel v časopise
Journal of Czech Physicians
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- Essential Hypertension – Syndrome, or Compensatory Mechanism
- Preoperative Preparation and Examinations Before Scheduled Cardiosurgical Intervention
- Psychomotor Speed and Speed of Searching in Semantic Memory
- Clinical Utility of Bone Markers in the Evaluation and Follow-up in Patients with Neoplastic Bone Diseases